Evidence map›Paper›PMID 34610580›Full record

Trial reportAging2021

Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.

Zihong Liang, Yanbo Jia, Lizhen Zhao, Runxiu Zhu, Xuemei He, Bagen Tong, Fan Yang, Lixia Hao, Pengfei Cui, Jun Yuan

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zihong LiangDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Yanbo JiaDepartment of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia 010030, People's Republic of China.
Lizhen ZhaoDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Runxiu ZhuDepartment of Neurology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Xuemei HeDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Bagen TongDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Fan YangDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Lixia HaoDepartment of Psychiatry, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Pengfei CuiDepartment of Psychiatry, Inner Mongolia Autonomous Region Third Hospital, Huhhot, Inner Mongolia 010050, People's Republic of China.
Jun YuanDepartment of Neurology, Inner Mongolia Autonomous Region People's Hospital, Huhhot, Inner Mongolia 010017, People's Republic of China.
Inner Mongolia People's Hospital · CNSecond Affiliated Hospital of Inner Mongolia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Agomelatine was a novel and melatonergic antidepressant. The present study was conducted to find out whether age was an important factor for agomelatine in treating depressed type 2 diabetes mellitus (T2DM) patients. In total, 193 depressed T2DM patients were included. There were 84 patients ranged from 27 years old to 49 years old (age phase I) (

Indexed as

Diabetes Mellitus, Type 2AcetamidesAdultAgedAgingAntidepressive Agents, Second-GenerationDepressionFemaleFluoxetineHumansHypnotics and SedativesMaleMiddle AgedNaphthalenesParoxetineAcetamidesagomelatineAntidepressive Agents, Second-GenerationFluoxetineHypnotics and SedativesNaphthalenesParoxetineagomelatinedepressionfluoxetineparoxetinetype 2 diabetes mellitus

Identifiers

PMID34610580
PMCPMC8544326
OpenAlexW3204626536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.